Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...

These four blue chip stocks with dependable, high-yield dividends should continue to deliver regardless of inflation.

Sales of the rotavirus vaccine, Rotateq, rose 25% to $193 million, while Pneumovax 23 (pneumococcal vaccine polyvalent) vaccine sales declined 51% to $68 million. Sales of Vaxneuvance, Merck’s ...

The American Academy of Pediatrics recommends routine immunization of infants with RotaTeq at 2, 4 and 6 months of age. The first dose should be administered between 6 and 12 weeks of age.

Merck MRK reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding ...

RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management ...

RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the ...

The concomitant administration of multiple vaccines at a single clinic visit reduces the number of required visits to healthcare providers and can improve compliance with vaccine recommendations ...

After hours: 15 November at 7:59 pm GMT-5 ...